AbbVie (ABBV) Assets (2012 - 2026)

AbbVie (ABBV) has reported Assets for 15 consecutive years, with $135.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets fell 1.51% year-over-year to $135.1 billion in Q2 2026; TTM through Jun 2026 was $135.1 billion, a 1.51% decrease from a year earlier, with the FY2025 full-year figure at $134.0 billion, down 0.89% from the prior year.
• Assets was $135.1 billion for Q2 2026 at AbbVie, down from $136.5 billion in the prior quarter.
• Over five years, Assets peaked at $148.9 billion in Q1 2024 and troughed at $133.9 billion in Q3 2025.
• A 5-year average of $138.3 billion and a median of $136.3 billion in 2023 frame the typical range for Assets.
• Across the five-year window, Assets grew 10.65% in 2024 and fell 8.54% in 2025, its largest moves.
• Over 5 years, Assets stood at $138.8 billion in 2022, then retreated by 2.95% to $134.7 billion in 2023, then advanced by 0.33% to $135.2 billion in 2024, then slipped by 0.89% to $134.0 billion in 2025, then rose by 0.86% to $135.1 billion in 2026.
• The last three Assets figures came in at $135.1 billion (Q2 2026), $136.5 billion (Q1 2026), and $134.0 billion (Q4 2025), per Business Quant data.